ERBB2 and breast cancer: However, for patients with HER2+ breast cancer, those with SLX4IPhigh/ hTERTlow had a worse prognosis than patients with SLX4IPlow/hTERThigh, which is consistent with the findings from the 2009 and 2013 studies on HER2 and ALT positivity discussed above [73,74].